TAVR for Aortic Valve Disease

Nanjing First Hospital, Nanjing Medical University5,000 enrolled

Overview

Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.

Study Type

OBSERVATIONAL

Enrollment

5,000

Conditions

Aortic Valve Disease

Interventions

transcatheter heart valveDEVICE

patients with severe aortic valve disease underwent transcatheter heart valve

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Clinical diagnosis of severe aortic stenosis or aortic regurgitation 2. Patients undergo transcatheter aortic valve replacement Exclusion Criteria: patients refuse the clinical follow-up

Outcomes

Primary Outcomes

all-cause death during follow-up

all-cause death during 5-year follow-up

Time frame: 5 years

Secondary Outcomes

cardiac death during follow-up

Cardiac death during 5-year follow-up

Time frame: 5 years

Central Contacts

Jun-Jie Zhang, MD

CONTACT

+86-25-52271350 jameszll@163.com

Jing Kan, MPH